- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
B. Metzler seel. Sohn & Co. AG Cuts Gilead Sciences Stock Holdings
The German investment firm reduced its stake in the biopharmaceutical company by 8.2% in the third quarter.
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
B. Metzler seel. Sohn & Co. AG, a German investment firm, reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.2% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 90,125 shares of the biopharmaceutical company's stock, valued at $10,004,000 at the end of the quarter.
Why it matters
Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Changes in institutional ownership of the company's stock can provide insights into market sentiment and potential future performance.
The details
According to the 13F filing, B. Metzler seel. Sohn & Co. AG sold 8,102 shares of Gilead Sciences during the third quarter. The firm now holds a total of 90,125 shares of the company's stock. Gilead Sciences has seen its stock price rise in recent months, with several analysts raising their price targets on the company's shares.
- The 13F filing covers the third quarter of 2026.
The players
B. Metzler seel. Sohn & Co. AG
A German investment firm that reduced its stake in Gilead Sciences, Inc. by 8.2% during the third quarter of 2026.
Gilead Sciences, Inc.
A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, including antiviral therapies for HIV and viral hepatitis.
The takeaway
The reduction in B. Metzler seel. Sohn & Co. AG's stake in Gilead Sciences could signal a shift in market sentiment towards the biopharmaceutical company, though the overall institutional ownership of the stock remains high. Investors will likely continue to monitor Gilead's performance and any further changes in institutional ownership.
